Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure?

By sjmartinez • October 18, 2023

John N, Ibrahim B, Ebaid M, Saab S. Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure? Hepat Med. 2023 Oct 12;15:185-193. doi: 10.2147/HMER.S371507. PMID: 37850074; PMCID: PMC10578169.

Tags: cholangiopathy, Cirrhosis, covid-19, Digestive Diseases, Fellow, liver injury, Publications, Thrombosis

Enhanced CTLA-4 blockade anti-tumor immunity with APG-157 combination in a murine head and neck cancer

Shin DS, Basak S, Veena MS, Comin-Anduix B, Bhattacharya A, Dong TS, Ko A, Han P, Jacobs J, Moatamed NA, Avila L, Pellegrini M, Wang[...]

Upregulated Matrisomal Proteins and Extracellular Matrix Mechanosignaling Underlie Obesity-Associated Promotion of Pancreatic Ductal Adenocarcinoma

Waldron RT, Lugea A, Chang HH, Su HY, Quiros C, Lewis MS, Che M, Ramanujan VK, Rozengurt E, Eibl G, Pandol SJ. Upregulated Matrisomal Proteins[...]

Cost effectiveness of hepatitis C direct acting agents

Shetty A, Lee M, Valenzuela J, Saab S. Cost effectiveness of hepatitis C direct acting agents. Expert Rev Pharmacoecon Outcomes Res. 2024 Apr 26. doi:[...]